Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)

Next Previous
Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nebokitug (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms PSC SPRING; The SPRING study
  • Sponsors Chemomab Therapeutics

Most Recent Events

  • 03 Mar 2025 According to Chemomab media release, completed successful FDA End-of-Phase 2 meeting following positive Nebokitug Phase 2 SPRING trial results in primary sclerosing cholangitis
  • 16 Oct 2024 According to a Chemomab Therapeutics media release, company announced that it will present an abstract discussing the results of the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2024. The conference will take place in San Diego, California, November 15 to 19, 2024.
  • 25 Jul 2024 According to a Chemomab Therapeutics media release, topline treatment results from Open Label Extension (OLE) portion of the study, which will include patients with up to 48-weeks of exposure to CM-101, are on track to be reported in the first quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top